Pancreatic Cancer Research

ResearcherUniversity of MinnesotaActive in the last 2 years

Kazuho Inoko

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6205-9890; OpenAlex author ID A5033954724. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Inhibition of fatty acid binding protein suppresses pancreatic cancer progression and metastasis. Co-author DOI 10.1038/s41598-025-11271-9↗
  2. Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model. Co-author DOI 10.1038/s41417-024-00810-7↗
  3. Interferon-expressing oncolytic adenovirus + chemoradiation inhibited pancreatic cancer growth in a hamster model. Co-author DOI 10.1111/cas.15903↗
  4. Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target. Co-author DOI 10.1158/1535-7163.mct-19-0491↗
  5. Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. Co-author DOI 10.1038/s41417-018-0020-7↗
  6. Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation. Co-author DOI 10.18632/oncotarget.21939↗
  7. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Canc… Co-author DOI 10.1158/0008-5472.can-14-2921↗
  8. Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. Co-author DOI 10.18632/oncotarget.5729↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takahiro Tsuchikawa · 6 shared papers, 2015–2024 · strength 0.47
  2. Toru Nakamura · 6 shared papers, 2015–2024 · strength 0.47
  3. Satoshi Hirano · 6 shared papers, 2015–2024 · strength 0.47
  4. Shuhei Shinoda · 2 shared papers, 2023–2025 · strength 0.45
  5. Mizuho Sato‐Dahlman · 2 shared papers, 2023–2025 · strength 0.45
  6. Masato Yamamoto · 2 shared papers, 2023–2025 · strength 0.45
  7. Toshiaki Shichinohe · 5 shared papers, 2015–2024 · strength 0.41
  8. Toshihiro Kushibiki · 4 shared papers, 2015–2020 · strength 0.25
  9. Hironobu Takano · 4 shared papers, 2015–2018 · strength 0.20
  10. Shintaro Takeuchi · 4 shared papers, 2015–2018 · strength 0.20
  11. Julia Davydova · 1 shared paper, 2023 · strength 0.19
  12. Nikita Sharma · 1 shared paper, 2023 · strength 0.19
  13. Hiroki Niwa · 1 shared paper, 2024 · strength 0.18
  14. Shoki Sato · 3 shared papers, 2015–2018 · strength 0.16
  15. Yoshitsugu Nakanishi · 1 shared paper, 2020 · strength 0.08
  16. Toshimichi Asano · 1 shared paper, 2020 · strength 0.08
  17. Shinya Tanaka · 1 shared paper, 2020 · strength 0.08
  18. Kyoko Hida · 1 shared paper, 2020 · strength 0.08
  19. Osamu Sato · 1 shared paper, 2017 · strength 0.05
  20. Shota Kuwabara · 1 shared paper, 2017 · strength 0.05
  21. Yusuke Nakamura · 1 shared paper, 2017 · strength 0.05
  22. Masato Ono · 1 shared paper, 2017 · strength 0.05
  23. Hiroshi Nishihara · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.